Endo International PLC (ENDP) Price Target Cut to $7.00

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) had its price target lowered by Cantor Fitzgerald from $9.00 to $7.00 in a research report report published on Friday. The firm currently has a neutral rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Oppenheimer Holdings, Inc. restated a hold rating on shares of Endo International PLC in a report on Sunday, July 23rd. ValuEngine cut Endo International PLC from a buy rating to a hold rating in a report on Friday, September 1st. Zacks Investment Research upgraded Endo International PLC from a hold rating to a buy rating and set a $9.75 target price for the company in a report on Wednesday, October 11th. Royal Bank Of Canada set a $9.00 target price on Endo International PLC and gave the company a hold rating in a report on Tuesday, October 17th. Finally, BidaskClub upgraded Endo International PLC from a sell rating to a hold rating in a report on Wednesday, July 19th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the company. Endo International PLC currently has a consensus rating of Hold and a consensus target price of $11.67.

Shares of Endo International PLC (NASDAQ ENDP) traded up $0.08 during mid-day trading on Friday, reaching $6.78. The company had a trading volume of 1,791,781 shares, compared to its average volume of 7,354,719. The stock has a market cap of $1,490.00, a PE ratio of 1.43 and a beta of 0.53. Endo International PLC has a 52 week low of $5.77 and a 52 week high of $18.63. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. Endo International PLC’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.01 EPS. research analysts anticipate that Endo International PLC will post 3.54 EPS for the current fiscal year.

WARNING: “Endo International PLC (ENDP) Price Target Cut to $7.00” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/14/endo-international-plc-endp-price-target-cut-to-7-00.html.

A number of hedge funds have recently bought and sold shares of ENDP. James Investment Research Inc. bought a new position in Endo International PLC during the 2nd quarter valued at approximately $113,000. Blair William & Co. IL bought a new position in Endo International PLC during the 2nd quarter valued at approximately $126,000. LMR Partners LLP bought a new position in Endo International PLC during the 3rd quarter valued at approximately $148,000. Point View Wealth Management Inc. increased its position in Endo International PLC by 16.6% during the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares in the last quarter. Finally, Riverhead Capital Management LLC increased its position in Endo International PLC by 64.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares in the last quarter. 90.50% of the stock is owned by institutional investors.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply